The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Official Title: A Phase 1 Dose-escalation Study of PSMA ADC in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer
Study ID: NCT01414283
Brief Summary: Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. For all subjects, PSMA ADC will be administered in four repeating cycles.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Name: Robert J Israel, MD
Affiliation: Progenics Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR